Health Economics›Non-small cell lung cancer›Induction therapy for locally advanced disease

Induction therapy for locally advanced disease

Non-small cell lung cancer · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
MIC Variant #01	—	R 8 193	21d	—	7.6 mo	4	R 32 771 PFS proxy	1
PEV Variant #01	—	R 3 411	21d	—	—	~3	~R 10 232 indirect	—

2 of 2 regimens shown